Erasca (ERAS) Common Equity (2020 - 2026)
Erasca posted quarterly Common Equity of $393.5 million for Q1 2026, down 1.5% year-on-year from $399.5 million in Q1 2025, and up 21.02% on a QoQ basis from $325.2 million in Q4 2025.
Erasca (ERAS) has 7 years of Common Equity data on file, last reported at $393.5 million in Q1 2026.
- For the quarter ending Q1 2026, Common Equity fell 1.5% year-over-year to $393.5 million; the trailing twelve-month figure through Mar 2026 stood at $393.5 million (down 1.5% YoY), and the FY2025 full-year result was $325.2 million, down 23.22% from the prior year.
- Common Equity for Q1 2026 stood at $393.5 million, up from $325.2 million in the prior quarter.
- Across five years, Common Equity topped out at $451.1 million in Q2 2024 and bottomed at $288.4 million in Q1 2024.
- The 5-year median for Common Equity is $386.5 million (2023), against an average of $379.6 million.
- The widest annual swing landed in 2022, when Common Equity soared 428.54%; it then decreased 25.37% in 2024.
- A 5-year view of Common Equity shows it stood at $411.9 million in 2022, then slipped by 23.11% to $316.7 million in 2023, then soared by 33.73% to $423.5 million in 2024, then dropped by 23.22% to $325.2 million in 2025, then advanced by 21.02% to $393.5 million in 2026.
- The last three Common Equity figures came in at $393.5 million (Q1 2026), $325.2 million (Q4 2025), and $347.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 393.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 393.53 Mn |
| Dec 31, 2025 | 325.17 Mn |
| Sep 30, 2025 | 347.89 Mn |
| Jun 30, 2025 | 372.26 Mn |
| Mar 31, 2025 | 399.50 Mn |
| Dec 31, 2024 | 423.50 Mn |
| Sep 30, 2024 | 450.04 Mn |
| Jun 30, 2024 | 451.09 Mn |
| Mar 31, 2024 | 288.41 Mn |
| Dec 31, 2023 | 316.69 Mn |
| Sep 30, 2023 | 338.98 Mn |
| Jun 30, 2023 | 362.71 Mn |
| Mar 31, 2023 | 386.45 Mn |
| Dec 31, 2022 | 411.85 Mn |
| Sep 30, 2022 | 365.32 Mn |
| Jun 30, 2022 | 395.07 Mn |
| Mar 31, 2022 | 424.66 Mn |
| Dec 31, 2021 | 456.53 Mn |
| Sep 30, 2021 | 482.99 Mn |
| Jun 30, 2021 | -150.00 Mn |
| Mar 31, 2021 | -129.26 Mn |
| Dec 31, 2020 | -113.98 Mn |
| Sep 30, 2020 | -52.82 Mn |
| Jun 30, 2020 | -42.55 Mn |